Endometrial cancer (EC), also known as uterine or corpus cancer, is the fourth most common gynecologic malignancy overall. In contrast to other solid tumors, the incidence of EC is rising. This is thought to be related to the increasing incidence of obesity, which is tightly linked to EC. Patients with EC who are diagnosed with early-stage disease can potentially achieve a survival rate of over 80%. Despite a high survival rate and potential cure for women whose EC is diagnosed early, racial minorities continue to have poor outcomes. In this activity, Shannon Westin, MD, MPH provides expert recommendations on how to manage patients with EC, including how to address and overcome healthcare disparities. Dr Westin also discusses how to stratify patients based on risk factors using tumor histology, and molecular testing recommendations using mismatch repair protein immunohistochemistry and gene mutation burden with microsatellite instability assays. In addition, this interactive video lecture uses patient case scenarios to illustrate an expert’s approach at formulating treatment recommendations for patients with advanced or recurrent disease and planning evidence-based approaches for mitigating side effects of novel therapies. Watch to the end to hear Dr Westin answer audience questions about prevention, diagnosis, and treatment.
Interactive video lecture
After completing this activity, participants should be better able to:
- Highlight existing healthcare disparities in the treatment and management of EC that affect survival outcomes
- Explain the risk factors, biomarkers, and molecular testing currently recommended for patients with EC
- Formulate treatment strategies for patients with advanced or recurrent EC based on safety and efficacy data for novel and emerging treatments
- Plan evidence-based approaches to mitigate adverse events of novel therapies for EC
Oncology NPs, PAs, and nurses
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Beth Sandy, MSN, CRNP, Abramson Cancer Center, Philadelphia, Pennsylvania
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until August 16, 2022. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Corinne Williams, PA-C, Northwestern University Feinberg School of Medicine, Chicago, Illinois
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program was cosupported by educational grants from Astellas and Pﬁzer; AstraZeneca; Bristol-Myers Squibb; Dendreon Pharmaceuticals LLC; Eisai; Epizyme Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Karyopharm Therapeutics; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncopeptides; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.; Regeneron Pharmaceuticals, Inc. and Sanoﬁ Genzyme; and Seagen Inc.
This activity is supported by an educational grant from Eisai, GlaxoSmithKline and Merck & Co., Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Ms Sandy: speakers bureau: AstraZeneca, Jazz, Merck, Takeda.
Dr Westin: consulting: Agenus, Circulogene, Eisai, Merck, Pfizer, Zentalis; consulting/research support: AstraZeneca, Clovis Oncology, Novartis, Roche/Genentech, Tesaro/GlaxoSmithKline; research support: ArQule, Bayer, Bio-Path, Cotinga Pharmaceuticals.
Ms Williams: consulting/speakers bureau: AbbVie, AstraZeneca.
None of the members of the PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- View the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 1.00 hour.
Release date: August 17, 2021
Expiration date: August 16, 2022
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 100621O-7G